argenx shares drop after trial of Vyvgart in Sjögren's disease is halted
argenx (NASDAQ:ARGX) shares dropped 15% after halting a Phase 3 trial of Vyvgart for Sjögren's disease due to futility. The trial failed to meet its primary endpoint, and Baird cut its price target to $823. Meanwhile, argenx reported positive Phase 2 results for FB102 in celiac disease, acquired via its $2.2B purchase of Forte Biosciences.
How this was made
The 30-second read
Why it matters
The abrupt halt triggered a ~15% share decline, prompting analysts to cut price targets and raising concerns about the company's pipeline momentum.
Market read
The trial failure is a material, first‑report event for a US‑listed biotech, likely driving short‑term price pressure and influencing sector sentiment.
What to watch
Potential upside from the positive FB102 Phase 2 results and the $2.2 bn Forte Biosciences acquisition could cushion the impact.
Background
argenx announced the discontinuation of its Phase 3 UNITY trial for Vyvgart after an independent data monitoring committee deemed it futile.
Ticker impact
ARGX shares fell ~15% after the company halted the Phase 3 UNITY trial of Vyvgart in Sjögren's disease.
likely continued downside as investors price in the failed trial
Clinical‑trial failure for a late‑stage program typically triggers sell‑offs, especially with a double‑digit intraday drop already observed.
Market effects
Biotech sector may see broader risk aversion toward late‑stage autoimmune programs.
US biotech stocks could face short‑term pressure.
Limited to investors tracking clinical‑trial outcomes; no immediate macro effect.
Counterpoint
If the celiac‑disease data for FB102 proves robust, the market may view the setback as a pivot rather than a terminal failure.
Key entities
- companyargenx SE
Biotech firm developing Vyvgart and FB102.
- drugVyvgart
Investigational therapy for Sjögren's disease.
- drugFB102
CD122 inhibitor showing positive Phase 2 data in celiac disease.
